Dose regimen of favipiravir for Ebola virus disease
- 27 November 2014
- journal article
- other
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 15 (2), 150-151
- https://doi.org/10.1016/s1473-3099(14)71047-3
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal modelAntiviral Research, 2014
- Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse modelAntiviral Research, 2014
- Favipiravir (T-705), a novel viral RNA polymerase inhibitorAntiviral Research, 2013
- Clinical Virology of Ebola Hemorrhagic Fever (EHF): Virus, Virus Antigen, and IgG and IgM Antibody Findings among EHF Patients in Kikwit, Democratic Republic of the Congo, 1995The Journal of Infectious Diseases, 1999